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Abstract
Aims The aim of this study was to investigate inpatient costs
of acute coronary syndromes (ACS) in Switzerland and to
assess the main cost drivers associated with this disease.
Methods and Results We used the national multicenter
registry AMIS (acute myocardial infarction in Switzerland)
which includes a representative number of 65 hospitals and
a total of 11.623 patient records. The following cost modules
were analyzed: hospital stay, percutaneous coronary inter-
ventions (PCI) and thrombolysis. Expenses were assessed
using data from official Swiss national statistical sources.
Mean total costs per patient were 12.101 Euro (median 10.929
Euro; 95% CI: 1.161–27.722 Euro). The length of stay ranged
from one to 129 days with a mean of 9.5 days (median
8.0 days; 95% CI: 1–23). Overall costs were independently
influenced by age, gender and existent co-morbidities, e.g.
cerebrovascular disease and diabetes (p<0.0001).
Conclusion Our study determined specific causes for the high
costs associated with hospital treatment on a large repre-
sentative sample. The results should highlight unnecessary
expenses and help policy makers to evaluate the base case
for a DRG (Diagnosis Related Groups) scenario in Switzer-
land. Cost weighting of the identified secondary diagnosis
should be considered in the calculation and coding of a
primary diagnosis for ACS.
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Introduction
CVD (cardiovascular disease) is a common and costly
medical condition in all populations. It is the leading cause
of death worldwide. Nearly 3.8 million men and 3.4 million
women worldwide die each year from coronary heart
disease. CVD causes over 4.35 million deaths in Europe
and over 1.9 million deaths in the European Union (EU)
each year. Nearly half of all deaths in Europe (49%) and the
EU (42%) arise from CVD. It is the main cause of years of
life lost from early death in Europe and the EU. A third of
the years of life lost from early death result from CVD.
Overall CVD is estimated to cost the EU economy 169
billion Euros annually of which approximately 62% is due
to health care expenses, 21% due to productivity losses and
17% due to informal care of people with CVD [1].
In Switzerland CVD is the most frequent cause of death.
It affects 42% of women and 35% of men and accounts for
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38% of all deaths. Between 1999 and 2002 more than 186
out of 100.000 inhabitants annually died from CVD [2].
According to the International Classification of Diseases
(ICD-10), 135.341 patients suffering from CVD had been
treated in Switzerland in 2004.
CVD accounted for 3.1% of all hospital diagnoses in 2004
in Switzerland. With 1.258391 in hospital care days CVD is
within the top three ranking of ICD related national hospital
stay [3]. The expenditures for inpatient treatment are expected
to rise from more than 25 million CHF (16.13 million Euros)
in 2005 to more than 27 million CHF (17.42 million Euros)
in 2007. Among the countries in the Organisation for Eco-
nomic Co-operation and Development (OECD), Switzerland
ranks second (11.5%) behind the USA (15%) in terms of
healthcare expense versus gross domestic product (GPD).
Switzerland (8 days) also ranks second behind Germany
(9 days) in terms of length of hospital stay [4].
The increasing health care budget draws public interest to
significant economic impacts on the Swiss health care system.
ACS (acute coronary syndrome) is a continuum of acute
ischemic cardiac conditions. ACS is defined as non-ST-
segment elevation myocardial infarction (NONSTEMI), ST-
segment elevation myocardial infarction (STEMI), and
unstable angina (UA) [5].
Only a few studies have compared the medical costs of
ACS from a European perspective, and involve only a small
non-representative number of Swiss data [1, 6, 7].
None of these studies identifies the main causes of ex-
penses in patients suffering from ACS within a nationwide
multicenter database of the Swiss population.
Analysis of factors that increase or decrease the length of
hospital stay of patients with underlying myocardial infarc-
tion is of interest from both a medical quality and pecuniary
standpoint. The implementation of DRGs will allow nation-
wide comparative assessments of resource use and costs.
The amount of money spent in CVD will be of particular
importance.
The DRG system fixes the amount of treatment on the
basis of discharge activity. This system is composed of
different major diagnostic categories which further compound
several DRG categories. A discharge in a DRG practiced
system receives a weight that has been given to this group.
This weight represents the average use of resources in rela-
tion to the discharge. These cost weights are determined by
using a trimming average for cost and the length of
hospitalization. A maximum and minimum hospitalization
length of time and cost for each DRG group is computed. For
this purpose a censured intersection is assessed. Exceeding
the length of stay from the trimming point in a given DRG
group connotes a defined extra cost for each bed day. The
aim of this study was to investigate inpatient costs of ACS in
Switzerland and to assess the main cost drivers associated
with this disease.
Methods
Patients
Calculations had been based on an AMIS database
population of 11.623 patients admitted to a hospital for
ACS from January 1997 until December 2005.
The AMIS registry collects and analyzes data of patients
with ACS in Switzerland in the pre-admission and hospital
phases. Emphasis is placed on the evaluation of risk factors,
diagnostics, urgent therapy strategies, and treatment of ACS.
Patients are grouped in the database on the basis of their
final diagnosis, which must comply with one of the three
following definition categories: AMI (acute myocardial in-
farction), symptoms or ECG (electrocardiogram) changes
compatible with ACS, or both, and cardiac enzymes (total
creatinine kinase [CK] or [CK-MB] at least twice the upper
limit of normal range); ACS with minimum necrosis (symp-
toms or ECG changes compatible with acute coronary syn-
drome, or both, and cardiac enzymes (total CK or CK-MB)
lower than twice the upper limit of normal range, and
positive troponin); and UA (symptoms or ECG changes
compatible with ACS, or both, and normal cardiac enzymes).
Cases that are unclear or non-cardiac cases are excluded.
The registry started in 1997 and continues to add patient
cases. To date, 65 of the 106 hospitals treating ACS in
Switzerland are enrolling patients, ranging from community
to large university hospitals. Participating centers add blind
data for each patient through a standardized internet or
paper based questionnaire. The data are centralized at the
Institute for Social and Preventive Medicine at the Univer-
sity of Zurich, where they are monitored for plausibility and
consistency. The registry was authorized by the Above-
Regional Ethics Committee for Clinical Studies and the
Swiss Board for Data Security.
The questionnaire comprises 140 items for each patient
and is completed by the coordinator of each institution.
It asks information regarding medical history and existing
co-morbidities, known cardiovascular risk factors, acute
symptoms, out of hospital management, clinical presentation,
early (first 48 h) in-hospital management, reperfusion
therapy, hospital course, diagnostic tests used or planned,
hospital length of stay, discharge medication and destination.
The documented data from 11.623 patients with ACS were
analyzed.
Cost evaluation
Reliable hospital related cost estimates are difficult to obtain
in Switzerland. Differences exist in measuring patient costs
among the individual Swiss cantons and in-between the
hospitals of each canton.
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Some hospitals balance accounts by prospective lump
compensation while others allocate individual performance.
Even the invoiced amount per entries varies between the
hospitals. Some cantons apply a singular flat rate (funded
half and half between the local canton and the insurance
company) and a per day rate. The flat rate includes all care
performed except prescription of high priced pharmaceu-
ticals, days spent on the intensive care unit (ICU) and high
priced implants (e.g. drug eluting stent).
These rates differ between the type of department (e.g.
surgery or rheumatology), on the level of insurance (private,
semi-private or compulsory health insurance) and the geo-
graphic policy territory of the involved health insurance
company. The insured patient is required by law to apply for
specific high cost treatments in the canton of residency. For
medical service outside of the canton a separate fee is applied
and calculated.
To obtain a nationwide representative overview we as-
sessed expenses using data from official Swiss national
statistics [8]. The cost evaluation was made from the per-
spective of a hospital. The calculation is based on adapted
average charges per hospital care day without investment
costs. These come from a division of the charges per hospital
care day without investment costs through the case mix
gross of the hospital.
One day of hospital care in a university hospital costs up
to 1.308 Euro while a smaller hospital charges 483 Euro.
One cause for the apparent tripling of cost is that the costs
in this indicator are not measured according to the severity
code of the medical condition. Patients suffering from critical
illness have longer hospital stays and require more nurse
care depending on the severity of the disease. A university
clinic also incurs expenditures for teaching, research and
development.
Statistics for average hospital care charges can be refined
by employing a case mix calculation. A case mix calculation
takes the severity code into account. By comparing the
average adapted costs and the average cost per hospital care
day with investment costs, the influence of the severity code
can be taken into account.
The type of activity and duties of a hospital have a huge
impact on the average costs per hospital day. Similar sized
hospitals (beds, personal, total charges) can feature varying
amounts of hospital per day fees. These depend on the type
of disease and treatment (acute versus long term treatment).
The effects can be taken into consideration by using a
weighting of the average costs per hospital care day through
the case mix gross. This indicator comes with DRG strings
attached. Each DRG group is allocated to a special case mix
that indicates the economic performance indicator related
to a reference average of one. Only inpatient cases of the
hospitals are considered while ambulant ones are excluded.
This model was generated for five categories of hospitals
arranged according to their size. The categories are defined
by the number of treated patients per year and the number
of medical specialist categories (Table 1).
Per day costs for a small hospital were averaged to 548
Euro. Larger hospitals averaged 806 Euros and centralized
hospitals averaged 758-up to 839 Euros per day. University
hospitals charge 1.129 Euro per day. The national average
charge for all types of hospitals, which acted as a calculation
base for the hospital charges in our evaluation, is 816 Euro
per care day (based on the latest collected case mix statistic
data, 2003). Using this method a flat rate is included in the
total.
Our hospital based perspective did not account for costs
associatedwithmorbidity ormortality (e.g. productivity losses).
Table 2 shows other parameters of the cost calculation.
Rates for ICU were computed to be 2.435 Euro per day.
PCI costs 1.548 Euro and the accrued expenses for
thrombolysis amounted to 1.161 Euro. These were estimat-
ed as an average peak cost for all available data. Swiss
francs were converted to Euro with an exchange rate of
1.55 (15.5.2006) [9].
Statistical analysis
Data concerning the costs and length of hospitalization were
analyzed according to different factors. Age, gender, co-
Table 1 Hospital size and calculation of case mix adapted charges per hospital care day (1999–2003) [4]
Hospital Code Number of treated
cases per year
Number medical
specialities
Expected number
of hospitals
Case mix adapted charges per
hospital care day in Euro
Centralized medical care type 1
university hospital
1 >30.000 ≥100 5 1.129
Centralized medical care type 2 2 9.000–30.000 100>∑specialist≥20 22 839
Primary medical care type 1 3 6.000–9.000 20>∑specialist≥10 28 758
Primary medical care type 2 4 3.000–6.000 10>∑specialist≥5 55 806
Primary medical care type 3 5 <3.000 <5 specialist 53 548
Hospital categories and service area: type 1 huge; type 2 middle; type 3 small
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morbidities, smoking status and body mass index (BMI) are
risk factors associated with ACS and have been positively
identified with having a correlation in previous studies [10–12].
All data were analyzed with SPSS (version 12.0) for
Windows NT.
An assessment of univariate associations between candidate
predictors and costs was performed by the non-parametric
Mann–Whitney rank sum test. T-test or ANOVA were used
for categorical independent variables. A two tailed proba-
bility value of p<0.05 was considered to be significant.
A multivariate linear regression model for predicting the
cost and length of stay was used for the following variables:
gender, age, BMI, insurance coverage, smoking, history of
ACS, co-morbidities, cardiac insufficiency NYHA III–IV,
peripheral vascular disease, cerebrovascular disease, diabe-
tes, renal disease, arterial hypertension and dyslipidemia.
Separate univariate linear models were first fitted for
each variable and then backwards eliminated against a
significance level of 0.05. Odds ratios were simultaneously
adjusted for all other predictors included in the multivariate
linear regression mode. Independent variables showing a
positive assignment to costs were treated as candidates for
multivariate regression analysis.
Descriptive statistics are presented as percentages for
discrete variables. For data not normally distributed a median
and an interquartile range is calculated. For normally
distributed data a mean confidence interval is calculated.
Calculations of total charges and the length of hospital stay
are indicated with both a mean and a median. Thus the best
estimated costs and duration of stay per patient and per
typical patient are reflected.
Results
We analyzed 11.623 patients admitted for ACS from January
1997 until December 2005. Of these patients, 73% were
male and 27% female. Of the patients analyzed, 10.827
patients were found to have an ECG ST-segment elevation
at hospital admission. Patients were treated in accordance
with international guidelines [13–16]. Table 3 illustrates the
baseline characteristics of the study population.
Patient population and co-morbidities
The mean age of the study patients was 64.4±13.3 years
(median 66.18 years; in males 63.12±12.99 years; median
Table 3 Baseline characteristics, co-morbidities and associated
prevalence of the study population
Number Percent
Hospital admission 11.623 100
Women 3.140 27
Men 8.483 73
Age
<65 5.492 47.3
≥65 6.131 52.7
BMI
<25 kg/m2 3.349 28.8
≥25 kg/m2 5.547 47.7
No answer 2.727 23.5
Smoking
Never 3.883 33.4
Former 2.489 21.4
Current 4.614 39.7
No answer 637 5.5
Killip classification
I 8.490 73
II 2.045 17.6
III 550 4.8
IV 336 2.9
No answer 202 1.7
ST segment elevation
Yes 10.827 93.2
No 777 6.7
No answer 19 0.2
Diabetes
Yes 2.160 18.6
No 9.063 78.0
No answer 400 3.4
Hypertension
Yes 5.740 49.4
No 5.380 46.3
No answer 503 4.3
Dyslipidemia
Yes 5.827 50.1
No 4.661 40.1
No answer 1.135 9.8
Table 2 Parameters of cost calculation and mean cost per patient for each resource category
Resource use Unit costs in Euro Number Cost mean Cost median Standard deviation % of total costs (%)
Hospitalization 816 11.623 6.906 5.713 6.632 57.07
ICU 2.435 9.569 4.151 2.435 4.717 34.30
Thrombolysis 1.161 3.347 334 NM 526 2.76
PCI 1.548 5.327 710 NM 772 5.87
Total 11.623 12.101 10.929 9.218 100
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63.20 years, and in females 71.36±12.32 years; median
73.66 years; p<0.001). The age distribution is illustrated in
Fig. 2.
The most frequent risk factors were age (older than
65 years; 52.7%), dyslipidemia (50.1%), hypertension
(49.4%), weight (BMI>25 kg/m2; 47%), current or former
smoking (39.7% respectively 21.4%) and a medical history
of cardiac events (27.4%).
Of these patients, 8.490 were in Killip class I (73%),
2.045 were coded for Killip class II while the rest of the
population had been in class III (n=550) and IV (=336).
The Killip classification is a score to risk stratify individuals
with an acute myocardial infarction. Killip class I includes
individuals with no clinical signs of heart failure; Killip class
II includes individuals with rales in the lungs, an S 3 gallop,
and elevated jugular venous pressure; Killip class III
describes individuals with frank pulmonary edema; Killip
class IV describes individuals in cardiogenic shock [17].
In-hospital procedures and events
In hospital procedures and outcomes are displayed in Table 4.
PCI was performed in 5.327 (45.83%) cases while 3.347
patients (28.80%) received thrombolysis. Nine thousand
five hundred sixty nine patients (82.33%) were treated in an
intensive care unit. There were 1.024 cases of in hospital
deaths (8.81%), whereas 10.597 (91.19%) were successful-
ly treated.
Three thousand four hundred forty seven patients (29.6%)
had complications during the hospital stay. Of these patients,
10.2% (n=1.185) went into a cardiogenic shock, 14.1% (n=
1.640) had recurrent ischemic episodes. 0.7% (n=87) were
admitted for unstable angina but had an acute infarction,
3.2% (n=376) suffered from a re-infarction and 3.3% (n=
386) sustained a cerebrovascular event. In our study 3.3%
(n=386) of the patients required temporary pacing, 4.9%
(n=569) needed heart massage and 3.7% (n=426) were
under mechanical circulatory support. Invasive mechanical
ventilation was performed in 5.8% (n=674) of the study
population and 6.1% (n=708) of the patients were defibril-
lated. The average length of stay in the ICU was 2.11 days
(range 0–48 days, standard deviation (SD): 1.947; 95%
confidence interval [CI] between 2.07 to 2.14).
Outcomes and predictors of costs
The hospital length of stay varied from zero to 129 days
with a mean of 9.48 days (median 8.0 days). Women had a
mean stay of 11.24 days (median 10 days, SD 8.61) while
men spent an average period of 8.87 days (median 8.0 days,
SD 7.71) in the hospital (p<0.0001).
Based on this length of stay the hospital costs (board and
lodging) accounted for a mean of 6.906 Euro (median 5.713
Euro) with a range from zero to 105.281 Euro (SD: 6.632
Euro). The percentiles calculated are as follows: 25th per-
centile: 1.632 Euro, 50th percentile: 5.713 Euro, 75th
percentile: 9.794 Euro. In 9.569 patient cases the additional
costs for ICU have been added. This expense component
amounted to a mean of 4.150 Euro and a median of 2.435
Euro. The standard deviation was 4.717 Euro while the
range varied from zero to 116.903 Euro. Expenses for PCI
and thrombolysis were calculated to be 1.548 Euro and
1.161 Euro.
Table 4 Outcomes and in hospital procedures
Outcome/procedure Number Percent
Death 1.024 8.81
Alive discharge 10.597 91.19
Patients received PCI 5.327 45.83
Patients received thrombolysis 3.347 28.80
Average days hospital stay 9.48
Average days stay women 11.24
Average days stay men 7.71
PCI men 4.136
PCI women 1.191
Thrombolysis men 2.563
Thrombolysis women 784
Temporary pacing 386
Heart massage 569
Mechanical support (IABP or other) 426
Intubation 674
Defibrillation 708
Patients treated on ICU 9.569 82.33
Average days on ICU 2.11
Fig. 1 Distribution of costs per treated ACS patient
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The mean cost per patient for each resource category is
reported in Table 2.
Based on calculations using data from official Swiss
national statistics (Table 1) the total expenditures per patient
varied between 0 Euro and 169.052 Euro with a mean of
12.101 Euro, a median of 10.929 Euro and a SD of 9.217
Euro. The 25th percentile was 5.960 Euro, the 50th was
10.929 Euro and the 75th was 15.494 Euro. The distribu-
tion of costs is depicted in Fig. 1.
The outcomes of co-morbidities and costs can be seen in
the univariate analysis in Table 5.
Multivariate linear regression adjusting for the classifi-
cation of high cost patients was performed afterwards and is
displayed in Table 6.
Of all the variables included in the model, the strongest
predictors of high-cost patient care was gender (p=0.005),
age (p=0.017), cerebrovascular disease (p=0.001) and dia-
betes (p<0.0001).
More than 60% of hospital costs are associated with ward
costs. A mean length of stay (9 days) on a normal ward costs
7.344 Euro. Diabetes and cerebrovascular disease increase
the costs about 20–40%.
Female patients have higher treatment costs than males how-
ever they had a higher mean age confound to be a risk factor.
Discussion
Hospital costing methods that adjust for differences in
length of stay require a significant large sample to attain
statistical power [18]. Our analysis is based on the data of
more than 10.000 patients. By including statistics from the
majority of hospitals in Switzerland, the AMIS registry
reflects a realistic pattern of the present cost calculation in
the management of ACS in the country. Findings about
reperfusion therapy of myocardial infarction and the asso-
ciation of dyslipidemia and concomitant risk factors with
in hospital mortality in ACS have been derived from data
on this registry [12, 19]. This ongoing multicenter project,
which offers a data input and analysis over the internet, is a
Table 5 Univariate analysis of the effect of co-morbidities on costs
Factor Cost (median), Euros Δ cost Interquartile ranges p values
Sex Women 11.426 842 11.745 <0.0001
Men 10.584 9.048
Age <65 10.500 900 8.136 <0.0001
≥65 11.400 9.436
BMI <25 10.513 97 8.483 0.929
≥25 10.610 8.148
Insurance Basic 9.226 13 8.161 0.197
Private 9.213 7.591
Smoking Yes 10.583 746 7.373 0.001
No 11.329 9.429
ST-elevation Yes 10.929 319 8.148 0.835
No 10.610 10.160
Heart rhythm Sinus rhythm 9.697 1.632 8.148 0.001
Atrial fibrillation 11.329 8.929
Prior myocardial infarction Yes 10.500 0 9.944 0.23
No 10.500 8.136
Co-morbidities Yes 9.755 542 10.168 0.001
No 9.213 7.332
Chronic heart failure None, NYHA I + II 9.697 1.115 8.148 0.808
NYHA III + IV 8.977 13.265
Peripheral vascular disease Yes 10.555 871 12.255 0.037
No 9.684 8.148
Cerebrovascular disease Yes 12.132 2.822 10.500 <0.0001
No 9.310 8.148
Diabetes Yes 11.316 2.103 10.051 <0.0001
No 9.213 8.136
Renal disease Yes 9.761 77 13.225 0.299
No 9.684 8.148
Hypertension Yes 11.303 445 8.952 0.064
No 10.858 7.677
Dyslipidemia Yes 10.858 471 7.816 0.87
No 11.329 8.965
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useful tool to examine actual trends in cardiology and asses
their impact on costs.
Our analysis is the first to focus on current costs in
treating ACS in face of the upcoming DRG implementation
in Switzerland and helps to predict high cost individuals.
Several crucial findings have emerged from this analysis.
First, we estimate the average cost of hospital treatment for
ACS to be about 12.101 Euro. These results appear to be in
line with the findings of other investigations [6, 7, 20, 21].
Levy et al. described an amount of 12.393 Euro for the cost
of treating a myocardial infarction in the Swiss population.
Their estimation, however, was based on a smaller sample
size [7]. Matsui and colleagues found the same duration of
stay in the intensive care unit (two days) in the late nineties,
but a longer hospitalization on the general ward in Switzer-
land (12 days). This reflects the trend towards shorter
residence periods on the general ward over the last years
[6, 22]. In addition Gandjour et al. [21] calculated the
personal costs on the critical care unit (physician hour 34.91
Euro; nursing hour 28.90 Euro) and general medicine ward
(physician hour 34.91 Euro; nursing hour 24.07 Euro). This
model could act as a valuable tool for further detailed
investigations of personnel expenditures.
Several important hospital resource benchmarks for a
DRG implementation can be derived from our findings.
This study found that the average cost of co-morbidities
like diabetes and cerebrovascular disease are higher than for
other secondary disorders.
The coding of both accompanying diseases should allow
for a higher reimbursement rate as they require a longer and
more expensive stay.
Females have a higher cost of treatment than males, but
represent an older set in our analyzed population. Age per
se was an indicator for higher charges and presupposes
adjusted DRG codes (Fig. 2). Besides the identified co-
morbidities, gender and age, the length of stay, obviously
influences the total expenses. There are opportunities to
improve the efficiency in the treatment of ACS. Interna-
tional studies recorded in European countries indicate longer
hospital stays and the more conservative use of early discharge
[23]. There is potential economic benefit of an earlier
discharge for low-risk patients, but they must be balanced
against a medical risk and a cost shift to the outpatient area.
Integration between inpatient and outpatient care could
result in a better outcome of post myocardial infarction
management and should be improved before entering the
DRG system. Since the release of the ACC/AHA Guideline
recommendations for treatment of NON STEMI ACS,
hospital prescription of clopidogrel in patients with NON
STEMI ACS who are treated with medical therapy alone
and those who undergo cardiac artery bypass graft surgery
(CABG) have increased. Most of these patients still do not
receive clopidogrel at discharge even though it is investigated
to be cost-effective [24, 25]. A time based risk management
for post myocardial infraction guides decision-making and
supports a discharge of four days after uncomplicated myo-
cardial infarction. Hospitalization of patients beyond three
days is uneconomical by conventional standards [26, 27].
Appropriate procedures and quick execution during the first
hospital stay would lead to global economic savings for the
public health system and could be clinically advantageous
for the patient.
Table 6 Multivariate linear regression for classification of high costs
Standardized coefficients t Sig. 95% Confidence interval for B
Beta Lower bound Upper bound
(Constant) 6.255 0.000 6.088.496 11.648.250
Sex −0.045 −2.802 0.005 −1.615.652 −285.340
Age 0.045 2.382 0.017 5.478 56.431
BMI −0.012 −0.732 0.464 −791.254 360.957
Insurance 0.013 0.860 0.390 −444.277 1.138.364
Smoking 0.026 1.495 0.135 −83.280 618.511
Prior myocardial infarction −0.012 −0.729 0.466 −868.767 397.949
Co-morbidities −0.014 −0.697 0.486 −979.094 465.300
Chronic heart failure (NYHA III + IV) 0.023 1.411 0.158 −436.858 2.678.008
Peripheral vascular disease 0.011 0.659 0.510 −966.456 1.945.655
Cerebrovascular disease 0.056 3.472 0.001 1.013.451 3.642.843
Diabetes 0.069 3.839 0.000 861.116 2.659.007
Renal disease 0.030 1.845 0.065 −77.520 2.553.083
Hypertension −0.010 −0.578 0.564 −751.155 409.276
Dyslipidemia 0.030 1.912 0.056 −14.066 1.116.772
F(14,4139)=6.15; p>; F=0.0001; R2 =0.143; adjusted
R2 =0.017
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Hospitalization is the focal point in the DRG system and
hence the value is basically independent of the hospital.
One critical point when using the DRG system is how to
correctly detect the classification of the patient during the
entire hospital stay (Table 7). Depending on the institution
and the first coding, a diagnosis might be a primary or a
secondary one. The diagnosis may also vary depending on
the type of department seeing the patient first. Therefore a
bias in the patient DRG can occur. In the preparing for the
DRG system the clinician has to cope with a lot of new
tasks. On the one hand all clinical findings have to be coded
and documented accurately. Knowledge about the economic
significance of the coding for the hospital and the health care
system is of particular importance. An important consider-
ation is the improvement of clinical procedures and their
time flow. Only hospitals that can work efficiently before the
expiration of the given DRG term will be able to survive the
severe competition. Based on experience in this new field,
many direct measures to optimising efficiency can be taken.
Labour efficiency and the use of standardized operational
sequences could provide economic gain without a loss in
health care quality. The coding of secondary diagnosis is
also crucial if reimbursements have to cover real costs.
Limitations
At the time of this study, 65 of 106 hospitals treating ACS
in Switzerland took part in the AMIS registry. This number
varied during the survey and may therefore not be entirely
representative for all hospitals in the country. Accordingly,
the absolute number of patients in this analysis may not
correspond to the national incidence of ACS leading to
hospitalization. Costly technology improvements and other
procedures (e.g. new costly drug eluting stents and cardiac
artery bypass graft surgery) have not been accounted for in
this survey. Only direct hospital costs have been analyzed
and estimated from billed charges. It is unlikely that our
approaches would consistently over- or underestimate the
cost of treating patients. Our method of assigning DRGs may
not capture all cost-relevant aspects. Our perspective
prevents any conclusion regarding the total health care or
social costs for these patients. The German (G)-DRG
Fig. 2 Median costs per treated ACS patient by age group
Table 7 Comparison of present costs and potential DRG reimbursement categories (adapted from the German [G]-DRG system) [28]
G-DRG Description Relation and
valuation factora
Reference value
in Euro (2007)
Average amount
in Euro
F 52 B Invasive diagnostic in acute myocardial infarction
with complex PCI + Stent intervention, five days
hospital stay, thereof one day ICUb
1.490 2.735,50 4.075,90
Current Swiss accounting
system
Invasive diagnostic in acute myocardial infarction
with complex PCI + Stent intervention, five days
hospital stay, thereof one day ICUc
Average amount
in Euro
12.101d
Other possible G-DRG
codings in ACS patients
receiving angiography
F 52 A Like F 52 B plus three severe co-morbidities 2.257 2.735,50 6.174,02
F 24 A Very complex PCI plus three severe co-morbidities 2.784 2.735,50 7.615,63
F 24 C Like F 24 A without severe co-morbidities 1.910 2.735,50 5.224,81
F 41 A Invasive diagnostic in ACS with severe co-morbidities 2.120 2.735,50 5.799,26
F 41 B Like F 41 A without severe co-morbidities 1.257 2.735,50 3.438,52
a Depending on hospital size and department
b Except separate ICU charge (only charged after 7 days)
c 1 day ICU included (2.435 Euro)
d Nationwide average for Switzerland
396 Cardiovasc Drugs Ther (2007) 21:389–398
system, which has been bought by Swiss DRG and adapted
for Switzerland, is based on a dual financing. Investments
e.g. buildings or equipment is funded by the federal
government and not included in the G-DRGs. Follow-up
was not available in this project, however a long term follow-
up questionnaire is being prepared and the outcomes will
soon be reported. Because of rapid evolutions of medical
technology and the accelerated progress in medical knowl-
edge, cost determination analyses have limited half-lives and
have to be updated continuously.
Public health policy is in great need of large high quality
national databases. Cost information in these models can
serve to focus attention on the assumptions underlying
clinical practice patterns and can help to identify areas in
which there is substantial disagreement about appropriate
evaluation and treatment strategies. The findings of analytic
models should be integrated into medical practice. They
can be used practically for physicians treating patients and
developing guidelines. They can also be used conceptually
for public health authorities to guide decision making in
healthcare systems.
To the best of our knowledge this analysis represents the
first effort to quantify the cost of hospitalization relating co-
morbidities, duration of stay and procedures for ACS in a
nationwide Swiss survey for an adapted G-DRG implemen-
tation. This country- specific cost model has relevance for
budgetary and planning purposes. The data can be used by
decision makers to asses the value and costs of therapies
and the impact of policy changes on patients with ACS.
Some of the determined predictors of high costs are prevent-
able co-morbidities and identify the importance of preven-
tion campaigns addressing the cardiometabolic risk factors.
Additional efforts investigating long term outcomes and
the burden for ambulatory treatment are needed to determine
a more exact cost-structure for a DRG implementation.
Setting up and testing outpatient systems for adequate treat-
ment as well as cost calculations are a prerequisite before the
introduction of DRGs.
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